Complement-Dependent Cytotoxicity (CDC) ex vivo Activity Assays at Physiological Levels
Daratumumab activity requires human complement & each sample has different levels.
Vivia assay preserves autologous Complement in each MM Native Environment sample

  • Vivia assay preserves autologous Complement in each MM Native Environment sample at bone marrow physiological concentrations (2x)
Figure 1
Figure 1. Daratumumab Killing Activity ± Complement: 20% autologous serum (red) vs 20% FBS (green). Enhanced activity with autologous serum in 2/5 samples
  • Activity (AUC) Correlates with CD38 Expression
Figure 2

Figure 2. Daratumumab activity in different MM BM patient samples shows a clear correlation with CD38 tumor expression.

  • Activity (AUC) Doesn´t Correlate with NK/Tumor Cell Ratio
Figure 3

Figure 3. Daratumumab activity in different MM BM patient samples shows no correlation with NK Cell/Tumor Ratio.

  • We preserve Native Environment
  • Improved CDC assessment using Native Environment that preserves autologous complement at physiological levels:
  • Enhanced CDC activity in 2/5 samples (figure 1 above)
  • Dara activity in MM BM patient samples reveals:
  • Expression activity dependence of target expression, i.e. CD38
  • No dependence activity of the NK Cell/ Tumor Ratio
Click Here